

Supplemental Table 2. CNS lesions at baseline (in patients with CNS metastases)

Categorical number of brain disease sites, n (%)	≥1 prior second-generation ALK TKI (EXP3B–5) (N = 95)	1 prior second-generation ALK TKI (EXP3B) (N = 13)	≥2 prior ALK TKIs (EXP4–5) (N = 82)
1–3	38 (40.0)	5 (38.5)	33 (40.2)
4–6	31 (32.6)	5 (38.5)	26 (31.7)
7–10	17 (17.9)	3 (23.1)	14 (17.1)
≥10	9 (9.5)	0	9 (11.0)

ALK, anaplastic lymphoma kinase; CNS, central nervous system; EXP, expansion cohort; TKI, tyrosine kinase inhibitor.